

# JosÃ© M Cuezva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7716269/publications.pdf>

Version: 2024-02-01

59  
papers

3,840  
citations

156536

32  
h-index

150775

59  
g-index

61  
all docs

61  
docs citations

61  
times ranked

5161  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy. <i>Molecular Metabolism</i> , 2022, 60, 101496.	3.0	7
2	The ATPase Inhibitory Factor 1 is a Tissue-Specific Physiological Regulator of the Structure and Function of Mitochondrial ATP Synthase: A Closer Look Into Neuronal Function. <i>Frontiers in Physiology</i> , 2022, 13, .	1.3	7
3	Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy. <i>Oncogenesis</i> , 2022, 11, 24.	2.1	7
4	Chronic inhibition of the mitochondrial ATP synthase in skeletal muscle triggers sarcoplasmic reticulum distress and tubular aggregates. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
5	Mitochondrial Elongation and OPA1 Play Crucial Roles during the Stemness Acquisition Process in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 3432.	1.7	8
6	Generation of mitochondrial reactive oxygen species is controlled by ATPase inhibitory factor 1 and regulates cognition. <i>PLoS Biology</i> , 2021, 19, e3001252.	2.6	22
7	Critical requirement of SOS1 RAS-GEF function for mitochondrial dynamics, metabolism, and redox homeostasis. <i>Oncogene</i> , 2021, 40, 4538-4551.	2.6	13
8	Effective therapeutic strategies in a preclinical mouse model of Charcotâ€“Marieâ€“Tooth disease. <i>Human Molecular Genetics</i> , 2021, 30, 2441-2455.	1.4	5
9	Reprogramming Oxidative Phosphorylation in Cancer: A Role for RNA-Binding Proteins. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 927-945.	2.5	13
10	Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells. <i>Carcinogenesis</i> , 2020, 41, 1113-1122.	1.3	6
11	Overexpression of Mitochondrial IF1 Prevents Metastatic Disease of Colorectal Cancer by Enhancing Anoikis and Tumor Infiltration of NK Cells. <i>Cancers</i> , 2020, 12, 22.	1.7	31
12	Coordinate Î²-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth. <i>Nature Communications</i> , 2020, 11, 3606.	5.8	62
13	Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fateâ€“Novel Insights. <i>Cancers</i> , 2020, 12, 3060.	1.7	11
14	Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells. <i>Cancers</i> , 2020, 12, 668.	1.7	13
15	Metabolic reprogramming and disease progression in cancer patients. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165721.	1.8	45
16	Dysfunctional oxidative phosphorylation shunts branchedâ€“chain amino acid catabolism onto lipogenesis in skeletal muscle. <i>EMBO Journal</i> , 2020, 39, e103812.	3.5	33
17	Changes in the Turnover of the Cellular Proteome during Metabolic Reprogramming: A Role for mtROS in Proteostasis. <i>Journal of Proteome Research</i> , 2019, 18, 3142-3155.	1.8	12
18	Tissueâ€“specific expression and postâ€“transcriptional regulation of the ATPase inhibitory factor 1 (IF1) in human and mouse tissues. <i>FASEB Journal</i> , 2019, 33, 1836-1851.	0.2	23

#	ARTICLE	IF	CITATIONS
19	Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma. <i>British Journal of Dermatology</i> , 2019, 181, 114-127.	1.4	19
20	The mitochondrial $\text{ATP}$ synthase is a shared drug target for aging and dementia. <i>Aging Cell</i> , 2018, 17, e12715.	3.0	109
21	MYC Induces a Hybrid Energetics Program Early in Cell Reprogramming. <i>Stem Cell Reports</i> , 2018, 11, 1479-1492.	2.3	31
22	A Review of the Inhibition of the Mitochondrial ATP Synthase by IF1 in vivo: Reprogramming Energy Metabolism and Inducing Mitohormesis. <i>Frontiers in Physiology</i> , 2018, 9, 1322.	1.3	66
23	The Role of Mitochondrial $\text{H}^+$ -ATP Synthase in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 53.	1.3	58
24	Different mitochondrial genetic defects exhibit the same protein signature of metabolism in skeletal muscle of PEO and MELAS patients: A role for oxidative stress. <i>Free Radical Biology and Medicine</i> , 2018, 126, 235-248.	1.3	10
25	Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis. <i>Journal of Translational Medicine</i> , 2017, 15, 29.	1.8	16
26	Regulation of the $\text{H}^+$ -ATP synthase by IF1: a role in mitohormesis. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2151-2166.	2.4	50
27	Mitochondrial ROS Production Protects the Intestine from Inflammation through Functional M2 Macrophage Polarization. <i>Cell Reports</i> , 2017, 19, 1202-1213.	2.9	146
28	Hif-1 $\alpha$ Knockdown Reduces Glycolytic Metabolism and Induces Cell Death of Human Synovial Fibroblasts Under Normoxic Conditions. <i>Scientific Reports</i> , 2017, 7, 3644.	1.6	53
29	Mitochondrial $\text{H}^+$ -ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. <i>Diabetologia</i> , 2017, 60, 2052-2065.	2.9	32
30	Overexpression of the ATPase Inhibitory Factor 1 Favors a Non-metastatic Phenotype in Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 69.	1.3	22
31	Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients. <i>PLoS ONE</i> , 2017, 12, e0178376.	1.1	16
32	Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. <i>Oncotarget</i> , 2016, 7, 490-508.	0.8	59
33	The ATPase Inhibitory Factor 1 (IF1): A master regulator of energy metabolism and of cell survival. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2016, 1857, 1167-1182.	0.5	101
34	Sensitivity to anti-Fas is independent of increased cathepsin D activity and adrenodoxin reductase expression occurring in NOS-3 overexpressing HepG2 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1182-1194.	1.9	1
35	Lack of GDAP1 Induces Neuronal Calcium and Mitochondrial Defects in a Knockout Mouse Model of Charcot-Marie-Tooth Neuropathy. <i>PLoS Genetics</i> , 2015, 11, e1005115.	1.5	70
36	Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases. <i>Journal of Translational Medicine</i> , 2015, 13, 65.	1.8	22

#	ARTICLE	IF	CITATIONS
37	PKA Phosphorylates the ATPase Inhibitory Factor 1 and Inactivates Its Capacity to Bind and Inhibit the Mitochondrial H <sup>+</sup> -ATP Synthase. <i>Cell Reports</i> , 2015, 12, 2143-2155.	2.9	104
38	In vivo inhibition of the mitochondrial H <sup>+</sup> -ATP synthase in neurons promotes metabolic preconditioning. <i>EMBO Journal</i> , 2014, 33, 762-778.	3.5	93
39	The H <sup>+</sup> -ATP synthase: A gate to ROS-mediated cell death or cell survival. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2014, 1837, 1099-1112.	0.5	91
40	Short-term exposure of nontumorigenic human bronchial epithelial cells to carcinogenic chromium(VI) compromises their respiratory capacity and alters their bioenergetic signature. <i>FEBS Open Bio</i> , 2014, 4, 594-601.	1.0	19
41	Mitochondria-Mediated Energy Adaption in Cancer: The H <sup>+</sup> -ATP Synthase-Geared Switch of Metabolism in Human Tumors. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 285-298.	2.5	59
42	Degradation of IF1 controls energy metabolism during osteogenic differentiation of stem cells. <i>EMBO Reports</i> , 2013, 14, 638-644.	2.0	62
43	The Mitochondrial ATPase Inhibitory Factor 1 Triggers a ROS-Mediated Retrograde Prosurvival and Proliferative Response. <i>Molecular Cell</i> , 2012, 45, 731-742.	4.5	214
44	AMPK and GCN2 <sup>α</sup> ATF4 signal the repression of mitochondria in colon cancer cells. <i>Biochemical Journal</i> , 2012, 444, 249-259.	1.7	56
45	Reverse phase protein microarrays quantify and validate the bioenergetic signature as biomarker in colorectal cancer. <i>Cancer Letters</i> , 2011, 311, 210-218.	3.2	28
46	Post-transcriptional regulation of the mitochondrial H <sup>+</sup> -ATP synthase: A key regulator of the metabolic phenotype in cancer. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2011, 1807, 543-551.	0.5	54
47	The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. <i>Journal of Translational Medicine</i> , 2011, 9, 19.	1.8	61
48	Selection of cancer cells with repressed mitochondria triggers colon cancer progression. <i>Carcinogenesis</i> , 2010, 31, 567-576.	1.3	123
49	Up-regulation of the ATPase Inhibitory Factor 1 (IF1) of the Mitochondrial H <sup>+</sup> -ATP Synthase in Human Tumors Mediates the Metabolic Shift of Cancer Cells to a Warburg Phenotype. <i>Journal of Biological Chemistry</i> , 2010, 285, 25308-25313.	1.6	178
50	The tumor suppressor function of mitochondria: Translation into the clinics. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 1145-1158.	1.8	89
51	Cancer Abolishes the Tissue Type-Specific Differences in the Phenotype of Energetic Metabolism. <i>Translational Oncology</i> , 2009, 2, 138-145.	1.7	53
52	Loss of the Mitochondrial Bioenergetic Capacity Underlies the Glucose Avidity of Carcinomas. <i>Cancer Research</i> , 2007, 67, 9013-9017.	0.4	162
53	Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. <i>Journal of Clinical Investigation</i> , 2007, 117, 719-729.	3.9	246
54	Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H <sup>+</sup> -ATP synthase. <i>Carcinogenesis</i> , 2006, 27, 925-935.	1.3	91

#	ARTICLE	IF	CITATIONS
55	Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. <i>Carcinogenesis</i> , 2005, 26, 2095-2104.	1.3	155
56	The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. <i>Carcinogenesis</i> , 2004, 25, 1157-1163.	1.3	131
57	Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. <i>Biochemical Journal</i> , 2004, 378, 17-20.	1.7	179
58	The bioenergetic signature of cancer: a marker of tumor progression. <i>Cancer Research</i> , 2002, 62, 6674-81.	0.4	317
59	Translational regulation of mitochondrial differentiation in neonatal rat liver. Specific increase in the translational efficiency of the nuclear-encoded mitochondrial beta-F1-ATPase mRNA. <i>Journal of Biological Chemistry</i> , 1993, 268, 1868-1875.	1.6	71